Home Page Overall Ranking ROE Ranking P/E Ranking Dividend Yield Capitalization Our eBook Our Book Contact










Isin GB0009252882
Ticker GSK.L
Company GLAXOSMITHKLINE
Currency £
Price
Aware Investor Index (AII) 290.7452
Recommendation STRONG BUY
P/E 44.99
ROE 100.00 %
Capitalization 293,410,164,996 $
Dividend Yield 2.09 %
P/S 9.76
AII Position 14
P/E Position 570
ROE Position 28
Capitalization Position 16
Dividend Yield Position 308
Sales 23,923,000,000 £
10-Year Average Earnings 5,192,400,000 £
Shares Outstanding 4,888,000,000
Equity 5,114,000,000 £
Dividend per Share 1 £
Industry Pharmaceutical
Country Great Britain
GLAXOSMITHKLINE Investor Relations Web Site http://www.gsk.com/investors.html







Sales:

YEAR MONTH AMOUNT
2015 12 23,923,000,000.00 £
2014 12 23,006,000,000.00 £
2013 12 26,505,000,000.00 £

Earnings:

YEAR MONTH AMOUNT
2015 12 8,422,000,000.00 £
2014 12 2,756,000,000.00 £
2013 12 5,436,000,000.00 £
2012 12 4,499,000,000.00 £
2011 12 5,208,000,000.00 £
2010 12 2,961,000,000.00 £
2009 12 6,283,000,000.00 £
2008 12 5,551,000,000.00 £
2007 12 5,310,000,000.00 £
2006 12 5,498,000,000.00 £

Equity:

YEAR MONTH AMOUNT
2015 12 5,114,000,000.00 £
2014 12 4,263,000,000.00 £
2013 12 7,812,000,000.00 £
2012 12 6,747,000,000.00 £
2011 12 8,827,000,000.00 £
2010 12 9,745,000,000.00 £
2009 12 10,742,000,000.00 £
2008 12 8,318,000,000.00 £
2007 12 9,910,000,000.00 £
2006 12 9,648,000,000.00 £

Shares Outstanding:

YEAR MONTH AMOUNT
2015 12 4,888,000,000
2014 12 4,865,000,000
2013 12 4,919,000,000
2012 12 4,913,000,000
2011 12 5,099,000,000
2010 12 5,128,000,000
2009 12 5,108,000,000
2008 12 5,226,000,000
2007 12 5,567,000,000
2006 12 5,700,000,000

 












Bloomberg News for GLAXOSMITHKLINE:

May 15, 2017
AstraZeneca Sues Executive After U.K. Rival Glaxo Lures Him Away
AstraZeneca Plc filed a lawsuit in a London court against former executive Luke Miels saying he breached his employment contract four months after rival drugmaker GlaxoSmithKline Plc announced it was poaching...
Mar 1, 2012
Omega Pharma Is Potential Buyer for GSK OTC Brands, L’Echo Says
European over-the-counter medicine brands that have been put up for sale by GlaxoSmithKline Plc, L’Echo reported, without saying where it got the information. The buyer is expected to pay more than...
Apr 25, 2012
Human Genome’s ‘Blockbuster’ Potential Undervalued in Bid
biotechnology company that spurned a $2.59 billion acquisition offer from GlaxoSmithKline Plc, said it undervalues the sales potential of leading treatment Benlysta. Glaxo said it doesn’t see the...
Mar 13, 2012
Drug Abitrage Lets Millionaire Mohringer Show Ferrari
GlaxoSmithKline Plc, says the parallel drug business confuses consumers about just what they’re buying and creates supply shortages in markets where traders such as Mohringer buy them. “GSK believes that...
Jul 26, 2011
GlaxoSmithKline, RBS Group, Ryanair: U.K., Irish Equity Preview
to 3,085.14, while Ireland’s ISEQ Index retreated 0.9 percent to 2,890.19. GlaxoSmithKline Plc (GSK LN): The pharmaceutical company’s Chief Executive Officer Andrew Witty said valuations on acquisitions...
Jul 7, 2011
Air France-KLM, Deutsche Bank, GSK, PPR: European Equity Preview
with the matter said. The shares rose less than 0.1 percent to 40.75 euros. GlaxoSmithKline Plc (GSK LN): The U.K.’s biggest drugmaker said proposals to cut costs and transfer part of its Panadol...
Oct 20, 2011
AK Steel, Crocs, Hospira, Lennar: U.S. Equity Movers
(HGSI US) rose 14 percent, the - most in the Russell 1000 Index, to $12.82. GlaxoSmithKline Plc (GSK LN), the U.K.’s largest drugmaker, may make a $25 a share cash offer for Rockville, Maryland-based...
Jul 3, 2011
Aegis, Diageo, Vodafone, Xstrata: U.K., Irish Equity Preview
Balfour Beatty Plc (BBY LN): Britain’s biggest builder is competing with bidders including Morubeni Corp. and Itochu Corp. for control of Bristol Water Group Plc, the Times reported without saying...
Jun 30, 2011
Glaxo, Roche Breast-Cancer Drugs Fail to Win U.K. Cost Backing
GlaxoSmithKline Plc’s Tyverb and Roche Holding AG’s Herceptin haven’t been proven effective when combined with a hormone to treat HER-2-positive breast cancer in older women, the U.K.’s health-cost...
Nov 30, 2011
Glaxo Scientists ‘Live or Die’ With Project in Research Overhaul
must let someone else finish the job. Solari, who until last month headed one of GlaxoSmithKline Plc’s targeted research units, is one of the casualties of the company’s new approach to drug discovery...


Google News for GLAXOSMITHKLINE:

Baxter Review - 12 hours ago
A Chartists Perspective on GlaxoSmithKline PLC (GSK.L)
GlaxoSmithKline PLC (GSK.L) has a current 14-day RSI of 55.22, the 7-day is 51.14, and the 3-day is resting at 39.61. The RSI, or Relative ...
Rives Journal - 2 hours ago
GlaxoSmithKline PLC (GSK.L) Technicals In Review
Let's view some technical levels on shares of GlaxoSmithKline PLC (GSK.L). Presently, the 14 day Williams %R is -72.57. Readings may range ...
Geneva Journal - 5 hours ago
GlaxoSmithKline PLC (GSK.L) Shares Moving On Volume
GlaxoSmithKline PLC (GSK.L) shares are moving today on volatility -0.65% or $-11.00 from the open. The LSE listed company saw a recent bid ...
Investomania (blog)
GlaxoSmithKline Begins Mepolizumab Phase III Study - Quick Facts
(RTTNews) - GlaxoSmithKline plc (GSK, GSK.L) announced the start of a phase III study with mepolizumab, an interleukin 5 antagonist, ...
Markets Insider - 1 day ago
Active Runner in Focus: GlaxoSmithKline PLC (GSK.L)
Shares of GlaxoSmithKline PLC (GSK.L) are moving on volatility today 0.26% or 4.50 from the open. The LSE listed company saw a recent bid ...
Concord Register - 2 days ago
GSK wins $235 million from Teva in Coreg patent trial
TA> to pay GlaxoSmithKline Plc <GSK.L> more than $235 million (185 million) for infringing a patent covering its blood pressure drug Coreg, ...
euronews - 6 days ago
GSK's new CEO aims to divest sports nutrition brand - sources
LONDON GlaxoSmithKline Plc's (GSK.L) new Chief Executive Officer Emma Walmsley is shaking up the British drugmaker's portfolio of smaller ...
Reuters UK - 5 days ago
GSK's new pharma head to join in September after AstraZeneca tussle
(Adds detail on Miels) By Ben HirschlerLONDON, June 19 (Reuters) - GlaxoSmithKline <GSK.L> has struck a deal for Luke Miels to start as its ...
Nasdaq - 19 Jun 2017
Australians among 19 on trial as Crown Resorts case opens in China
British drugmaker GlaxoSmithKline PLC <GSK.L> was fined nearly $500 million in 2014 and food maker OSI saw employees jailed last year.
euronews
UK Stocks-Factors to watch on June 20
GSK: GlaxoSmithKline GSK.L has struck a deal for Luke Miels to start as its new head of pharmaceuticals in September, following a lengthy ...


Back